What is the bonus history of the Achyut Healthcar?

Achyut Healthcare's recent bonus history includes a 4:10 ratio announced on December 10, 2024, and a 1:2 ratio issued on April 25, 2023.

Achyut Healthcare has a notable bonus history. The most recent bonus issue was a 4:10 ratio announced for December 10, 2024. Prior to that, on April 25, 2023, the company issued a bonus in a 1:2 ratio. If you have any more questions about the company or its financial activities, feel free to ask!

Has Achyut Healthcar declared dividend?

No Dividend History Available

Is Achyut Healthcar overvalued or undervalued?

As of May 30, 2025, Achyut Healthcar is considered a risky investment due to its overvaluation indicated by a PE ratio of 82.45, negative operational efficiency ratios, and poor returns on capital and equity, despite a recent positive stock return.

As of 30 May 2025, Achyut Healthcar's valuation grade has moved from does not qualify to risky, indicating a significant shift in its perceived financial health. The company is currently deemed overvalued, particularly highlighted by its PE ratio of 82.45, which is substantially higher than peers like MMTC Ltd. at 119.39 and Optiemus Infracom Ltd. at 82.35. Additionally, Achyut's EV to EBIT and EV to EBITDA ratios are both at -82.07, suggesting severe operational inefficiencies.<BR><BR>The company's ROCE stands at -0.72% and ROE at 1.79%, further underscoring its struggles in generating returns for shareholders. Compared to its peers, Achyut Healthcar's valuation metrics are concerning, especially when juxtaposed with PTC India Ltd., which has a PE ratio of just 9.02 and is classified as very attractive. Despite a recent positive stock return of 5.11% over the past week compared to the Sensex's 1.37%, the overall trend indicates that Achyut Healthcar remains a risky investment, with its long-term performance trailing behind the broader market.

What is the technical trend for Achyut Healthcar?

As of April 23, 2025, Achyut Healthcar's trend is mildly bearish, with mixed signals from indicators like the MACD, Bollinger Bands, and moving averages, suggesting some positive momentum but overall weakness.

As of 23 April 2025, the technical trend for Achyut Healthcar has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, suggesting some positive momentum, while the monthly MACD is mildly bearish, indicating a potential longer-term weakness. The Bollinger Bands are signaling a mildly bearish stance on both weekly and monthly time frames. Daily moving averages also reflect a mildly bearish trend. The Dow Theory shows no trend on the weekly chart but is mildly bullish on the monthly, which adds some complexity to the overall view. The RSI shows no signals on both time frames, indicating a lack of momentum. Overall, the current stance is mildly bearish with mixed signals across different indicators.

Who are the peers of the Achyut Healthcar?

Achyut Healthcar's peers include Mercury Labs, Ind-Swift, Source Natural, Bharat Immunolog, Makers Labs, Sunil Healthcare, Biofil Chemicals, Onyx Biotec, and Ajooni Biotech. In terms of performance, Achyut Healthcar has a 1-year return of 13.27%, higher than Biofil Chemicals (-29.77%) but lower than Ind-Swift (-20.10%).

Peers: The peers of Achyut Healthcar are Mercury Labs, Ind-Swift, Source Natural, Bharat Immunolog, Makers Labs., Sunil Healthcare, Biofil Chemicals, Onyx Biotec, and Ajooni Biotech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Mercury Labs, while Average management risk is found at Biofil Chemicals and Onyx Biotec, and the rest have Below Average management risk. Good growth is seen at Source Natural, while Average growth is noted at Onyx Biotec, and the rest have Below Average growth. Excellent capital structure is present at Mercury Labs, Good capital structure is found at Source Natural and Biofil Chemicals, while the rest have Below Average capital structure.<BR><BR>Return Snapshot: Achyut Healthcar has a 1-year return of 13.27%, which is higher than the lowest peer, Biofil Chemicals, at -29.77%, and lower than the highest peer, Ind-Swift, at -20.10%. Additionally, the six-month return is negative for Mercury Labs, Ind-Swift, Bharat Immunolog, Makers Labs., Biofil Chemicals, and Achyut Healthcar.

Who are in the management team of Achyut Healthcar?

As of March 2022, the management team of Achyut Healthcar includes Jigen Jagdishbhai Modi (Managing Director & CFO), Mahendra C Raycha (Chairman), Akshit Raycha (Non-Executive Director), Amisha Jigen Modi (Executive Director), and independent directors Rutvik Sanjaykumar Thakkar and Sonu Lalitkumar Jain. They oversee the company's operations and strategic direction.

As of March 2022, the management team of Achyut Healthcar includes the following individuals:<BR><BR>1. Jigen Jagdishbhai Modi - Managing Director & CFO<BR>2. Mahendra C Raycha - Chairman & Non-Executive Director<BR>3. Akshit Raycha - Non-Executive Director<BR>4. Amisha Jigen Modi - Executive Director<BR>5. Rutvik Sanjaykumar Thakkar - Independent Non-Executive Director<BR>6. Sonu Lalitkumar Jain - Independent Non-Executive Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

What does Achyut Healthcar do?

Achyut Healthcare Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 1996, with no recent sales or profit data available. Its market cap is INR 94 Cr, and it has a P/E ratio of 95.00.

Overview: <BR>Achyut Healthcare Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>Achyut Healthcare Limited was incorporated as 'Achyut Securities Private Limited' on January 11, 1996. The company name was changed to 'Achyut Healthcare Private Limited', with a fresh Certificate of Incorporation issued on November 26, 2002. There is no sales and profit data available for the latest quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 94 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 95.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.01 <BR>Return on Equity: 1.79% <BR>Price-to-Book: 2.93 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the top shareholders of the Achyut Healthcar?

The top shareholders of Achyut Healthcar include Mahendra C Raycha Huf as the largest promoter with 10.21%, and Dharm Prakash Tripathi as the highest public shareholder at 16.26%. Individual investors hold 39.82% of shares, while foreign institutional investors account for 8.14%, with no pledged promoter holdings or mutual funds involved.

The top shareholders of Achyut Healthcar include a mix of promoters and public investors. The majority shareholders are the promoters, with Mahendra C Raycha Huf being the promoter with the highest holding at 10.21%. The highest public shareholder is Dharm Prakash Tripathi, who holds 16.26%. Additionally, individual investors collectively hold 39.82% of the shares, while foreign institutional investors (FIIs) hold 8.14% through three different entities. There are no pledged promoter holdings, and no mutual funds are involved in the company's shareholding.

How big is Achyut Healthcar?

As of 24th July, Achyut Healthcare Ltd has a market capitalization of 125.00 Cr, categorizing it as a Micro Cap company. Recent financial data, including Net Sales and Net Profit, is unavailable, but as of March 2024, Shareholder's Funds are 30.75 Cr and Total Assets are 30.95 Cr.

As of 24th July, Achyut Healthcare Ltd has a market capitalization of 125.00 Cr, which categorizes it as a Micro Cap company.<BR><BR>There is no valid financial data available for the latest quarterly performance, including Net Sales and Net Profit for the latest four quarters.<BR><BR>The reporting period for the balance sheet is March 2024, with Shareholder's Funds amounting to 30.75 Cr and Total Assets valued at 30.95 Cr.

When is the next results date for Achyut Healthcar?

Achyut Healthcar will announce its results on 16 October 2025.

Achyut Healthcar will declare its results on 16 October 2025.

How has been the historical performance of Achyut Healthcar?

Achyut Healthcar's historical performance shows fluctuating financial metrics, with net sales peaking at 6.14 Cr in March 2024 before declining to 3.05 Cr in March 2025. The company maintained a zero-debt status while experiencing operating losses and an increase in total liabilities and assets during this period.

Answer:<BR>The historical performance of Achyut Healthcar shows a fluctuating trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Achyut Healthcar's net sales have varied significantly, with a peak of 6.14 Cr in March 2024, followed by a decline to 3.05 Cr in March 2025. The total operating income mirrored this trend, reaching 6.14 Cr in March 2024 and dropping to 3.05 Cr in March 2025. The company experienced operating losses, with an operating profit (PBDIT) of 0.72 Cr in March 2025, slightly down from 0.76 Cr in March 2024. Profit before tax also showed a slight decrease from 0.74 Cr in March 2024 to 0.70 Cr in March 2025, while profit after tax increased from 0.50 Cr to 0.55 Cr during the same period. The total liabilities rose from 30.95 Cr in March 2024 to 32.58 Cr in March 2025, reflecting an increase in trade payables and current liabilities. Total assets also increased from 30.95 Cr to 32.58 Cr, primarily driven by growth in current assets, which amounted to 12.06 Cr in March 2025, down from 21.47 Cr in March 2024. The company maintained a zero-debt status throughout the years, indicating no long-term or short-term borrowings.

Which are the latest news on Achyut Healthcar?

Why is Achyut Healthcar falling/rising?

As of 03-Dec, Achyut Healthcare Ltd's stock price is at 5.45, reflecting a 4.05% decline. Despite a strong year-to-date performance, recent trends show short-term struggles and downward pressure, although increased investor participation indicates some interest.

As of 03-Dec, Achyut Healthcare Ltd's stock price is falling, currently at 5.45, which reflects a decrease of 0.23 or 4.05%. This decline is evident in the stock's performance today, where it underperformed its sector by 3.26%. Over the past week, the stock has decreased by 3.88%, contrasting with the Sensex, which has only fallen by 0.59%. <BR><BR>While the stock has shown strong performance year-to-date with a gain of 37.63%, its recent trends indicate a struggle, particularly in the short term, as it is lower than the 5-day, 20-day, and 50-day moving averages. However, it remains above the 100-day and 200-day moving averages, suggesting some longer-term strength. <BR><BR>Additionally, there has been a notable increase in investor participation, with delivery volume rising by 125% against the 5-day average, indicating some interest despite the current price decline. Overall, the combination of recent underperformance relative to the sector and the short-term moving averages suggests that the stock is currently experiencing downward pressure.